Our findings, which demonstrate elevated BACE-1 levels in T2DM rats, align with this evidence, and the reduction of these elevated BACE-1 levels in SITG-treated T2DM brains further supports the neuroprotective effects of SITG. Here, BACE1 is linked to type 2 diabetes mellitus.